Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on May 10, 2025
First 5 California and First 5 San Diego Announce Stronger Starts Statewide Day of Action with Family Event
EIN Presswire
·
May 10, 2025
First 5 California and First 5 San Diego hosted a joint event today to commemorate Stronger Starts Statewide Day of Action 2025 SAN DIEGO, CA, UNITED STATES, May 10, 2025 /EINPresswire.com/ -- First 5 California and First 5 San Diego hosted a joint …
California Dispensaries Redefine Cannabis Retail Through Innovation and Community Engagement
EIN Presswire
·
May 10, 2025
818 Brands, Gradus Hollywood, and The Syndicate Tarzana Showcase Distinctive Approaches to Customer Experience and Local Connection LOS ANGELES, CA, UNITED STATES, May 10, 2025 /EINPresswire.com/ -- As California’s cannabis industry continues to evolve, …
Chronicle Associates Presents: Pursuit of Freedom – A Memoir of Courage and Reinvention
EIN Presswire
·
May 10, 2025
Chronicle Associates Presents: From Tehran to Triumph: Fariba Kalantari’s Inspiring Memoir “Pursuit of Freedom” Chronicles the Journey of Reinvention and Hope HOUSTON, TX, UNITED STATES, May 10, 2025 /EINPresswire.com/ -- Pursuit of Freedom: A Memoir …
Surgeon General's Warning: Social Media Risks Demand Comprehensive Youth Mental Health Support
EIN Presswire
·
May 10, 2025
U.S. Surgeon General warns of social media’s harm to youth mental health, urging action to curb risks like anxiety, depression, and cyberbullying. CA, UNITED STATES, May 10, 2025 /EINPresswire.com/ -- The U.S. Surgeon General’s Advisory on Social Media …
The Role of Hair Transplantation in Boosting Self-Esteem and Confidence – Smile Hair Clinic's Expertise
EIN Presswire
·
May 10, 2025
ISTANBUL, TURKEY, May 10, 2025 /EINPresswire.com/ -- Hair loss is a common issue that affects millions of people worldwide, and its impact goes beyond just physical appearance. It can significantly affect one’s self-esteem and confidence, leading many to …
Akero Therapeutics présente les résultats de la 96e semaine de l’essai clinique de phase 2b SYMMETRY sur l’éfruxifermine chez des patients atteints de cirrhose compensée causée par une stéatohépatite associée à un dysfonctionnement métabolique (MASH), …
GlobeNewswire
·
May 10, 2025
SOUTH SAN FRANCISCO, État de Californie, 10 mai 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ : AKRO), une société en phase clinique développant des traitements révolutionnaires pour les patients atteints de maladies métaboliques graves et dont …
Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der…
GlobeNewswire
·
May 10, 2025
SOUTH SAN FRANCISCO, Kalifornien, May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), ein in der klinischen Phase tätiges Unternehmen, das bahnbrechende Therapien für Patienten mit schwerwiegenden Stoffwechselkrankheiten entwickelt, …
MEDVi Under Review: Best GLP-1 Semaglutide & Terzepatide Compound Solution for Personalized Weight Loss
GlobeNewswire
·
May 10, 2025
New York, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: The growing challenges with traditional weight loss methods and why most diets fail What GLP-1 receptor agonists like Semaglutide and Tirzepatide are and how they support …
Sumatra Slim Belly Tonic Reviews: 2025 Real User Reviews Analyzed & Verified (Blue Tonic for Weight Loss)
GlobeNewswire
·
May 10, 2025
LOS ANGELES, May 10, 2025 (GLOBE NEWSWIRE) -- Losing weight these days can feel more difficult than ever. Despite trying countless diets, workout routines, and the latest supplements, many people still struggle with stubborn belly fat that just won't go …
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
GlobeNewswire
·
May 10, 2025
Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress 65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk …